Seres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection Treatment
By Ben Glickman
Shares of Seres Therapeutics rose early Tuesday after the company said it had received Fast Track Designation from the U.S. Food and Drug Administration for its therapeutic candidate.
The stock was up 15% to $1.79 in pre-market trading. Shares are up 62% in the last month, but have fallen 71% in the last year.
The Cambridge, Mass.-based developer of microbiology therapeutics said SER-155 is a microbiome therapeutic meant to prevent gastrointestinal-associated bacterial infections and reduce cases of severe acute graft-versus-host disease in immunocompromised patients receiving stem-cell transplants.
The company said it is expecting the readout from the second cohort in a Phase 1b trial of the therapeutic in the third quarter.
Seres said fourth-quarter sales of VOWST, another microbiome therapeutic approved by the FDA in April, were about $10.4 million and reflected a gross-to-net reduction of 11%.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 09, 2024 07:55 ET (12:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth